{"id":3369,"date":"2026-09-01T21:59:07","date_gmt":"2026-09-01T20:59:07","guid":{"rendered":"https:\/\/seamlessbio.de\/?p=3369"},"modified":"2026-09-01T21:59:09","modified_gmt":"2026-09-01T20:59:09","slug":"msc-expansion-hpl-vs-fbs-data-comparison","status":"publish","type":"post","link":"https:\/\/seamlessbio.de\/de\/msc-expansion-hpl-vs-fbs-data-comparison\/","title":{"rendered":"MSC Expansion \u2014 hPL vs FBS"},"content":{"rendered":"<p><!--\nWORDPRESS BLOG POST\nSlug: msc-expansion-hpl-vs-fbs-data-comparison\nSEO Title: MSC Expansion \u2014 hPL vs FBS \u2014 The Data-Driven Comparison | SeamlessBio\nMeta Description: A comprehensive comparison of human platelet lysate and FBS for MSC expansion \u2014 proliferation rate, ISCT criteria, immunomodulatory potency, and regulatory compliance.\nFocus Keyword: MSC expansion hPL vs FBS comparison\nAdditional Keywords: human platelet lysate MSC expansion, FBS vs hPL mesenchymal stem cell, hPL MSC proliferation ISCT criteria, xeno-free MSC manufacturing\nCategory: Cell Therapy \u00b7 ATMP \u00b7 MSC\n--><\/p>\n<style>\n.sb-bp{font-family:-apple-system,BlinkMacSystemFont,\"Segoe UI\",Roboto,sans-serif;max-width:780px;margin:0 auto;padding:0 0 60px;color:#202020;line-height:1.75}\n.sb-bp .lede{font-size:18px;font-weight:500;color:#3a4a50;border-left:4px solid #18b7b2;padding-left:20px;margin:0 0 32px;line-height:1.65}\n.sb-bp h2{font-size:24px;font-weight:800;margin:44px 0 14px;color:#111;padding-bottom:10px;border-bottom:2px solid #e2eceb}\n.sb-bp h3{font-size:18px;font-weight:700;margin:32px 0 10px;color:#18b7b2}\n.sb-bp p{margin:0 0 18px}\n.sb-bp ul,.sb-bp ol{margin:0 0 18px;padding-left:24px}\n.sb-bp li{margin-bottom:8px}\n.sb-bp table{width:100%;border-collapse:collapse;font-size:14px;margin:20px 0 28px;display:block;overflow-x:auto}\n.sb-bp th{background:#18b7b2;color:#fff;text-align:left;padding:10px 14px;font-weight:700;white-space:nowrap}\n.sb-bp td{padding:10px 14px;border-bottom:1px solid #e2eceb;vertical-align:top}\n.sb-bp tr:last-child td{border-bottom:none}\n.sb-bp td:first-child{font-weight:600;color:#111}\n.sb-bp a{color:#18b7b2;text-decoration:none;font-weight:600}\n.sb-bp strong{color:#111}\n.sb-bp .box{background:#f1faf9;border-left:4px solid #18b7b2;border-radius:0 12px 12px 0;padding:20px 24px;margin:28px 0}\n.sb-bp .warn{background:#fff8e1;border-left:4px solid #f59e0b;border-radius:0 12px 12px 0;padding:20px 24px;margin:28px 0}\n.sb-bp .cta-box{background:linear-gradient(135deg,#e4f6f5,#f4fbfb);border:1px solid rgba(24,183,178,.2);border-radius:16px;padding:28px;margin-top:44px;text-align:center}\n.sb-bp .cta-box h3{color:#111;margin:0 0 10px;font-size:20px}\n.sb-bp .cta-box p{color:#5b6b71;margin:0 0 18px}\n.sb-bp .cta-btns{display:flex;justify-content:center;gap:12px;flex-wrap:wrap}\n.sb-bp .btn{display:inline-block;background:#18b7b2;color:#fff!important;padding:10px 22px;border-radius:8px;font-weight:700;font-size:14px;text-decoration:none!important}\n.sb-bp .btn-o{display:inline-block;border:2px solid #18b7b2;color:#18b7b2!important;padding:8px 22px;border-radius:8px;font-weight:700;font-size:14px;text-decoration:none!important}\n<\/style>\n<div class=\"sb-bp\">\n<p class=\"lede\">The evidence base comparing human platelet lysate (hPL) and FBS for mesenchymal stem cell (MSC) expansion has grown substantially over the past decade. The conclusion is remarkably consistent across studies, cell sources, and laboratories: hPL at 5% outperforms FBS at 10% for MSC proliferation rate, and produces MSCs with equivalent or superior immunomodulatory potency. This post summarises the key data and explains the biology behind it.<\/p>\n<h2>Why MSC expansion medium matters<\/h2>\n<p>MSCs for clinical use must meet the ISCT (International Society for Cell Therapy) criteria for MSC identity \u2014 plastic adherence, specific surface marker expression (CD73+, CD90+, CD105+; CD34\u2212, CD45\u2212, CD14\u2212, HLA-DR\u2212), and tri-lineage differentiation potential. Beyond identity, clinical MSC products must demonstrate potency \u2014 the ability to suppress T cell proliferation and modulate macrophage polarisation, which is the primary therapeutic mechanism in GvHD, Crohn&#8217;s disease, and other inflammatory indications.<\/p>\n<p>The choice of expansion medium directly affects both the efficiency of manufacturing (expansion fold, population doubling time) and the quality of the product (potency markers, phenotype stability, exhaustion status). A medium that drives fast expansion at the cost of reduced potency is counterproductive.<\/p>\n<h2>Proliferation \u2014 the consistent finding<\/h2>\n<p>Across more than 30 published comparative studies of hPL vs. FBS for MSC expansion (bone marrow, adipose, umbilical cord, Wharton&#8217;s Jelly sources), the proliferation data is highly consistent:<\/p>\n<table>\n<thead>\n<tr>\n<th>Parameter<\/th>\n<th>FBS (10%)<\/th>\n<th>hPL (5%)<\/th>\n<th>Advantage<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Population doubling time (BM-MSC)<\/td>\n<td>48\u201372h<\/td>\n<td>28\u201342h<\/td>\n<td>hPL: 30\u201350% faster<\/td>\n<\/tr>\n<tr>\n<td>Population doubling time (AT-MSC)<\/td>\n<td>40\u201360h<\/td>\n<td>24\u201336h<\/td>\n<td>hPL: 30\u201340% faster<\/td>\n<\/tr>\n<tr>\n<td>Population doubling time (UC-MSC)<\/td>\n<td>36\u201348h<\/td>\n<td>20\u201332h<\/td>\n<td>hPL: 25\u201340% faster<\/td>\n<\/tr>\n<tr>\n<td>Total expansion fold (14 days)<\/td>\n<td>10\u201350\u00d7<\/td>\n<td>50\u2013200\u00d7<\/td>\n<td>hPL: 2\u20135\u00d7 higher<\/td>\n<\/tr>\n<tr>\n<td>Passages to clinical dose<\/td>\n<td>P5\u2013P8<\/td>\n<td>P3\u2013P5<\/td>\n<td>hPL: 2\u20133 fewer passages<\/td>\n<\/tr>\n<tr>\n<td>Cell viability<\/td>\n<td>90\u201395%<\/td>\n<td>93\u201398%<\/td>\n<td>Comparable \/ hPL slight advantage<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The faster proliferation in hPL is primarily driven by higher concentrations of human PDGF-AB and PDGF-BB \u2014 the primary MSC mitogens \u2014 released from platelet alpha granules. PDGF receptor signalling (PDGFR\u03b1\/\u03b2) drives MSC proliferation through the PI3K\/Akt and MAPK\/ERK pathways. Human PDGF signals more efficiently through human PDGFRs than bovine PDGF in FBS \u2014 explaining the consistent proliferation advantage across MSC sources and laboratories.<\/p>\n<h2>ISCT criteria \u2014 phenotype stability<\/h2>\n<p>A critical concern when changing expansion medium is whether MSCs maintain their identity criteria. Published data consistently shows that hPL-expanded MSCs maintain ISCT surface marker criteria (CD73+, CD90+, CD105+; lineage negative) equivalently to FBS-expanded MSCs at the same passage number. No published study has reported loss of ISCT identity criteria in hPL-expanded MSCs compared to FBS.<\/p>\n<p>Importantly, hPL-expanded MSCs at P5 show equivalent or better marker stability than FBS-expanded MSCs at P8 \u2014 because fewer passages are required to reach the same expansion fold, reducing the cumulative replicative stress on the cells.<\/p>\n<h2>Immunomodulatory potency \u2014 the key clinical attribute<\/h2>\n<p>MSC therapeutic mechanism is primarily paracrine \u2014 secretion of prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO), TGF-\u03b2, IL-10, and HGF that suppress T cell proliferation and polarise macrophages toward an anti-inflammatory M2 phenotype. Potency is measured by T cell suppression assay (co-culture of MSCs with stimulated PBMCs, measuring CFSE dilution or \u00b3H-thymidine incorporation) and by IDO activity (kynurenine assay).<\/p>\n<table>\n<thead>\n<tr>\n<th>Potency marker<\/th>\n<th>FBS-expanded MSCs<\/th>\n<th>hPL-expanded MSCs<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>T cell suppression (MLR suppression %)<\/td>\n<td>50\u201375% suppression at 1:10 MSC:PBMC<\/td>\n<td>60\u201385% suppression at 1:10 MSC:PBMC<\/td>\n<\/tr>\n<tr>\n<td>IDO activity (kynurenine\/tryptophan ratio)<\/td>\n<td>Comparable after IFN-\u03b3 priming<\/td>\n<td>Comparable or slightly higher after IFN-\u03b3 priming<\/td>\n<\/tr>\n<tr>\n<td>PGE2 secretion<\/td>\n<td>Comparable<\/td>\n<td>Comparable or slightly higher<\/td>\n<\/tr>\n<tr>\n<td>Macrophage polarisation (M2:M1 ratio)<\/td>\n<td>Comparable<\/td>\n<td>Comparable<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div class=\"box\">\n<strong>Summary:<\/strong> hPL-expanded MSCs are not just faster to produce \u2014 they show equivalent or superior immunomodulatory potency compared to FBS-expanded MSCs at the same passage number. The combination of higher expansion rate and maintained potency makes hPL the preferred choice for clinical MSC manufacturing from both a productivity and quality perspective.\n<\/div>\n<h2>Lot-to-lot variability \u2014 the underappreciated advantage of hPL<\/h2>\n<p>FBS lot-to-lot variability is well-documented and requires extensive lot qualification before each new FBS lot is introduced into a clinical MSC manufacturing process. A new FBS lot that fails MSC potency or expansion qualification can halt production for weeks while an alternative lot is sourced and qualified.<\/p>\n<p>hPL from a large pooled donor population (typically 40\u201380 donors per lot) has significantly lower lot-to-lot variability in growth factor composition compared to FBS \u2014 because pooling averages out individual platelet donor variability. Published head-to-head comparisons of hPL lot variability show 2\u20133\u00d7 lower coefficient of variation for MSC expansion rate between hPL lots compared to FBS lots from the same supplier.<\/p>\n<h2>Regulatory pathway \u2014 why hPL is now the preferred choice for clinical MSC<\/h2>\n<p>EMA Advanced Therapy Guidelines, FDA Guidance for ATMP manufacturing, and the International Pharmaceutical Excipients Council (IPEC) all encourage elimination of animal-derived components from ATMP manufacturing. For clinical MSC products, hPL provides:<\/p>\n<ul>\n<li><strong>Xeno-free compliance:<\/strong> no bovine components \u2014 eliminates TSE\/BSE documentation burden<\/li>\n<li><strong>Human-derived material:<\/strong> collected from screened donors with IRB clearance \u2014 acceptable under EMA ATMP guidelines as a human-origin raw material<\/li>\n<li><strong>GMP-grade availability:<\/strong> GMP hPL with full batch manufacturing records, donor documentation, viral testing, and sterility testing is available from qualified suppliers<\/li>\n<li><strong>Reduced immunogenic risk:<\/strong> no residual bovine proteins on the MSC surface after expansion \u2014 reducing theoretical risk of xenogenic immune response in the patient<\/li>\n<\/ul>\n<h2>Practical considerations for switching from FBS to hPL<\/h2>\n<p><strong>Fibrinogen management:<\/strong> Add heparin at 2 IU\/mL to hPL-containing medium to prevent fibrin gel formation. Alternatively, use fibrinogen-depleted hPL. This is the most common technical issue encountered during the FBS-to-hPL transition and is easily solved.<\/p>\n<p><strong>Concentration:<\/strong> Start with 5% hPL. Some protocols use 7.5\u201310% hPL for the first passage from a fresh biopsy, then reduce to 5% for subsequent passages. Higher concentrations rarely improve expansion beyond 5% for most MSC sources.<\/p>\n<p><strong>Seeding density:<\/strong> hPL-expanded MSCs reach confluency faster \u2014 adjust seeding density downward by 20\u201330% or shorten passage intervals when switching from FBS to hPL to avoid over-confluence.<\/p>\n<p><strong>Lot qualification:<\/strong> hPL lots still require qualification before clinical use \u2014 but the qualification panel is simpler than FBS because there are no bovine-specific markers to test. Essential qualification tests: sterility, mycoplasma (PCR), HIV\/HBV\/HCV NAT, endotoxin (LAL), total protein, MSC expansion performance test on a reference MSC line.<\/p>\n<div class=\"cta-box\">\n<h3>Human Platelet Lysate for MSC Expansion \u2014 Research and GMP Grade<\/h3>\n<p>SeamlessBio supplies human platelet lysate (hPL) for MSC expansion in research and GMP grade \u2014 xeno-free, full donor documentation, IRB clearance, batch reservation up to 24 months.<\/p>\n<div class=\"cta-btns\">\n<a href=\"https:\/\/seamlessbio.de\/de\/menschliches-thrombozytenlysat\/\" class=\"btn-o\">Lysat aus menschlichen Blutpl\u00e4ttchen (hPL) \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/what-is-human-platelet-lysate-hpl\/\" class=\"btn-o\">What is hPL? \u2014 Complete Definition \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/ressourcen\/blog\/human-platelet-lysate-hpl-fbs-replacement-guide\/\" class=\"btn-o\">hPL Complete Guide \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/what-is-msc-mesenchymal-stem-cell\/\" class=\"btn-o\">What is MSC? \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/what-is-atmp\/\" class=\"btn-o\">What is ATMP? \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/kontakt\/\" class=\"btn-o\">Request hPL Sample or Quote \u2192<\/a>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>The evidence base comparing human platelet lysate (hPL) and FBS for mesenchymal stem cell (MSC) expansion has grown substantially over the past decade. The conclusion is remarkably consistent across studies, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-3369","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MSC Expansion \u2014 hPL vs FBS \u2014 The Data-Driven Comparison<\/title>\n<meta name=\"description\" content=\"A comprehensive comparison of human platelet lysate and FBS for MSC expansion \u2014 proliferation rate, ISCT criteria, immunomodulatory potency, and regulatory compliance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/seamlessbio.de\/de\/msc-expansion-hpl-vs-fbs-data-comparison\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSC Expansion \u2014 hPL vs FBS \u2014 The Data-Driven Comparison\" \/>\n<meta property=\"og:description\" content=\"A comprehensive comparison of human platelet lysate and FBS for MSC expansion \u2014 proliferation rate, ISCT criteria, immunomodulatory potency, and regulatory compliance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/seamlessbio.de\/de\/msc-expansion-hpl-vs-fbs-data-comparison\/\" \/>\n<meta property=\"og:site_name\" content=\"SeamlessBio\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T20:59:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T20:59:09+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"5\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/msc-expansion-hpl-vs-fbs-data-comparison\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/msc-expansion-hpl-vs-fbs-data-comparison\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/person\\\/cd959a5b0b21c02c26d6ffef79f0d529\"},\"headline\":\"MSC Expansion \u2014 hPL vs FBS\",\"datePublished\":\"2026-09-01T20:59:07+00:00\",\"dateModified\":\"2026-09-01T20:59:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/msc-expansion-hpl-vs-fbs-data-comparison\\\/\"},\"wordCount\":1024,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/msc-expansion-hpl-vs-fbs-data-comparison\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/msc-expansion-hpl-vs-fbs-data-comparison\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/msc-expansion-hpl-vs-fbs-data-comparison\\\/\",\"name\":\"MSC Expansion \u2014 hPL vs FBS \u2014 The Data-Driven Comparison\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\"},\"datePublished\":\"2026-09-01T20:59:07+00:00\",\"dateModified\":\"2026-09-01T20:59:09+00:00\",\"description\":\"A comprehensive comparison of human platelet lysate and FBS for MSC expansion \u2014 proliferation rate, ISCT criteria, immunomodulatory potency, and regulatory compliance.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/msc-expansion-hpl-vs-fbs-data-comparison\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/msc-expansion-hpl-vs-fbs-data-comparison\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"name\":\"SeamlessBio\",\"description\":\"Expert for biological materials for pharma, vaccines and research organizations\",\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlessbio.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":[\"Organization\",\"Place\",\"ProfessionalService\"],\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\",\"name\":\"SeamlessBio\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"logo\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/msc-expansion-hpl-vs-fbs-data-comparison\\\/#local-main-organization-logo\"},\"image\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/msc-expansion-hpl-vs-fbs-data-comparison\\\/#local-main-organization-logo\"},\"address\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/msc-expansion-hpl-vs-fbs-data-comparison\\\/#local-main-place-address\"},\"telephone\":[\"+49 (851) 37932226\"],\"contactPoint\":{\"@type\":\"ContactPoint\",\"telephone\":\"+49 (851) 37932226\",\"email\":\"info@seamlessbio.de\"},\"openingHoursSpecification\":[{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Monday\",\"Tuesday\",\"Wednesday\",\"Thursday\",\"Friday\"],\"opens\":\"09:00\",\"closes\":\"17:00\"},{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Saturday\",\"Sunday\"],\"opens\":\"00:00\",\"closes\":\"00:00\"}],\"email\":\"info@seamlessbio.de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/person\\\/cd959a5b0b21c02c26d6ffef79f0d529\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\\\/\\\/seamlessbio.de\"],\"url\":\"https:\\\/\\\/seamlessbio.de\\\/de\\\/author\\\/admin\\\/\"},{\"@type\":\"PostalAddress\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/msc-expansion-hpl-vs-fbs-data-comparison\\\/#local-main-place-address\",\"streetAddress\":\"Dr.-Ernst-Derra-Str. 4\",\"addressLocality\":\"Passau\",\"postalCode\":\"94036\",\"addressRegion\":\"Bavaria\",\"addressCountry\":\"DE\"},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/msc-expansion-hpl-vs-fbs-data-comparison\\\/#local-main-organization-logo\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/134428046-2.png\",\"contentUrl\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/134428046-2.png\",\"width\":973,\"height\":288,\"caption\":\"SeamlessBio\"}]}<\/script>\n<meta name=\"geo.placename\" content=\"Passau\" \/>\n<meta name=\"geo.region\" content=\"Deutschland\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MSC Expansion \u2014 hPL vs FBS \u2014 The Data-Driven Comparison","description":"A comprehensive comparison of human platelet lysate and FBS for MSC expansion \u2014 proliferation rate, ISCT criteria, immunomodulatory potency, and regulatory compliance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/seamlessbio.de\/de\/msc-expansion-hpl-vs-fbs-data-comparison\/","og_locale":"de_DE","og_type":"article","og_title":"MSC Expansion \u2014 hPL vs FBS \u2014 The Data-Driven Comparison","og_description":"A comprehensive comparison of human platelet lysate and FBS for MSC expansion \u2014 proliferation rate, ISCT criteria, immunomodulatory potency, and regulatory compliance.","og_url":"https:\/\/seamlessbio.de\/de\/msc-expansion-hpl-vs-fbs-data-comparison\/","og_site_name":"SeamlessBio","article_published_time":"2026-09-01T20:59:07+00:00","article_modified_time":"2026-09-01T20:59:09+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"admin","Gesch\u00e4tzte Lesezeit":"5\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/seamlessbio.de\/msc-expansion-hpl-vs-fbs-data-comparison\/#article","isPartOf":{"@id":"https:\/\/seamlessbio.de\/msc-expansion-hpl-vs-fbs-data-comparison\/"},"author":{"name":"admin","@id":"https:\/\/seamlessbio.de\/#\/schema\/person\/cd959a5b0b21c02c26d6ffef79f0d529"},"headline":"MSC Expansion \u2014 hPL vs FBS","datePublished":"2026-09-01T20:59:07+00:00","dateModified":"2026-09-01T20:59:09+00:00","mainEntityOfPage":{"@id":"https:\/\/seamlessbio.de\/msc-expansion-hpl-vs-fbs-data-comparison\/"},"wordCount":1024,"commentCount":0,"publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/seamlessbio.de\/msc-expansion-hpl-vs-fbs-data-comparison\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/seamlessbio.de\/msc-expansion-hpl-vs-fbs-data-comparison\/","url":"https:\/\/seamlessbio.de\/msc-expansion-hpl-vs-fbs-data-comparison\/","name":"MSC Expansion \u2014 hPL vs FBS \u2014 The Data-Driven Comparison","isPartOf":{"@id":"https:\/\/seamlessbio.de\/#website"},"datePublished":"2026-09-01T20:59:07+00:00","dateModified":"2026-09-01T20:59:09+00:00","description":"A comprehensive comparison of human platelet lysate and FBS for MSC expansion \u2014 proliferation rate, ISCT criteria, immunomodulatory potency, and regulatory compliance.","breadcrumb":{"@id":"https:\/\/seamlessbio.de\/msc-expansion-hpl-vs-fbs-data-comparison\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/seamlessbio.de\/msc-expansion-hpl-vs-fbs-data-comparison\/"]}]},{"@type":"WebSite","@id":"https:\/\/seamlessbio.de\/#website","url":"https:\/\/seamlessbio.de\/","name":"SeamlessBio","description":"Experte f\u00fcr biologische Materialien f\u00fcr die Pharmaindustrie, Impfstoffe und Forschungseinrichtungen","publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlessbio.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":["Organization","Place","ProfessionalService"],"@id":"https:\/\/seamlessbio.de\/#organization","name":"SeamlessBio","url":"https:\/\/seamlessbio.de\/","logo":{"@id":"https:\/\/seamlessbio.de\/msc-expansion-hpl-vs-fbs-data-comparison\/#local-main-organization-logo"},"image":{"@id":"https:\/\/seamlessbio.de\/msc-expansion-hpl-vs-fbs-data-comparison\/#local-main-organization-logo"},"address":{"@id":"https:\/\/seamlessbio.de\/msc-expansion-hpl-vs-fbs-data-comparison\/#local-main-place-address"},"telephone":["+49 (851) 37932226"],"contactPoint":{"@type":"ContactPoint","telephone":"+49 (851) 37932226","email":"info@seamlessbio.de"},"openingHoursSpecification":[{"@type":"OpeningHoursSpecification","dayOfWeek":["Monday","Tuesday","Wednesday","Thursday","Friday"],"opens":"09:00","closes":"17:00"},{"@type":"OpeningHoursSpecification","dayOfWeek":["Saturday","Sunday"],"opens":"00:00","closes":"00:00"}],"email":"info@seamlessbio.de"},{"@type":"Person","@id":"https:\/\/seamlessbio.de\/#\/schema\/person\/cd959a5b0b21c02c26d6ffef79f0d529","name":"admin","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/seamlessbio.de"],"url":"https:\/\/seamlessbio.de\/de\/author\/admin\/"},{"@type":"PostalAddress","@id":"https:\/\/seamlessbio.de\/msc-expansion-hpl-vs-fbs-data-comparison\/#local-main-place-address","streetAddress":"Dr.-Ernst-Derra-Str. 4","addressLocality":"Passau","postalCode":"94036","addressRegion":"Bavaria","addressCountry":"DE"},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/seamlessbio.de\/msc-expansion-hpl-vs-fbs-data-comparison\/#local-main-organization-logo","url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/134428046-2.png","contentUrl":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/134428046-2.png","width":973,"height":288,"caption":"SeamlessBio"}]},"geo.placename":"Passau","geo.region":"Deutschland"},"_links":{"self":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/3369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/comments?post=3369"}],"version-history":[{"count":1,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/3369\/revisions"}],"predecessor-version":[{"id":3370,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/3369\/revisions\/3370"}],"wp:attachment":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/media?parent=3369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/categories?post=3369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/tags?post=3369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}